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ABSTRACT
Background: The mitochondrial DNA mutation
m.1555A>G predisposes to permanent idiosyncratic
aminoglycoside-induced deafness that is independent
of dose. Research suggests that in some families,
m.1555A>G may cause non-syndromic deafness,
without aminoglycoside exposure, as well as reduced
hearing thresholds with age (age-related hearing loss).
Objectives: To determine whether adults with
m.1555A>G have impaired hearing, a factor that
would inform the costebenefit argument for genetic
testing prior to aminoglycoside administration.
Design: Population-based cohort study.
Setting: UK.
Participants: Individuals from the British 1958 birth
cohort.
Measurements: Hearing thresholds at 1 and 4 kHz at
age 44e45 years; m.1555A>G genotyping.
Results: 19 of 7350 individuals successfully genotyped
had the m.1555A>G mutation, giving a prevalence of
0.26% (95% CI 0.14% to 0.38%) or 1 in 385 (95% CI 1
in 714 to 1 in 263). There was no significant difference
in hearing thresholds between those with and without
the mutation. Single-nucleotide polymorphism analysis
indicated that the mutation has arisen on a number of
different mitochondrial haplogroups.
Limitations: No data were collected on
aminoglycoside exposure. For three subjects, hearing
thresholds could not be predicted because information
required for modelling was missing.
Conclusions: In this cohort, hearing in those with
m.1555A>G is not significantly different from the
general population and appears to be preserved at
least until 44e45 years of age. Unbiased
ascertainment of mutation carriers provides no
evidence that this mutation alone causes
non-syndromic hearing impairment in the UK. The
findings lend weight to arguments for genetic testing
for this mutation prior to aminoglycoside
administration, as hearing in susceptible individuals is
expected to be preserved well into adult life. Since
global use of aminoglycosides is likely to increase,
development of a rapid test is a priority.
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ARTICLE SUMMARY
Article focus
- Individuals who have the m.1555A>G mutation
are exquisitely sensitive to rapid-onset hearing
loss after receiving aminoglycosides at normal
therapeutic levels.
- We sought to determine whether a cohort of
mature individuals with the m.1555A>G muta-
tion have hearing loss by their mid-40s because
the mutation has been reported to cause later-
onset less severe hearing loss in people who
have never been exposed to aminoglycosides.
We wished to determine whether genetic
screening prior to aminoglycoside administration
is justified.
Key messages
- This study demonstrates the prevalence of
m.1555A>G to be 1 in 385 (95% CI 1 in 714
to 1 in 263) in the 1958 British birth cohort,
confirming that this mutation occurs frequently
in Caucasian populations.
- The hearing of individuals with the m.1555A>G
mutation is no different to that of the general
population at age 44e45 years, in contrast to
previous reports which suggested that hearing
decreases with age in people with m.1555A>G;
any such effect is not large and likely to be
subject to previous ascertainment bias.
- These findings lend weight to the argument for
genetic testing for the m.1555A>G mutation
prior to aminoglycoside administration in order
to prevent avoidable hearing loss.
Strengths and limitations of this study
- Hearing data have been collected prospectively,
which avoids some of the biases inherent in
studies related to deafness and hearing loss.
- A potential limitation of the study was that data
on aminoglycoside exposure were not collected.
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INTRODUCTION
Aminoglycosides are widely used for treatment of and
prophylaxis against serious Gram-negative infections.
They are used in many situations including neonatal
septicaemia especially in premature babies where they
are often first-line treatment, surgical prophylaxis in
b-lactam-allergic patients of all ages, febrile neutropenia,
septic shock and drug-resistant tuberculosis. They are
well known to be ototoxic (ie, toxic to the cochlea and
the vestibular system) and nephrotoxic, and therefore,
drug levels are monitored to ensure that they are within
recommended limits. However, one in 500 people has
a maternally inherited genetic mitochondrial DNA
(mtDNA) mutation, termed m.1555A>G, which predis-
poses to extreme idiosyncratic hypersensitivity to
aminoglycosides, resulting in permanent and profound
deafness.1 2 In such patients, standard doses with drug
levels within the therapeutic range cause severe irreversible
ototoxicity.
It is also reported that m.1555A>G can cause hearing
loss even in the absence of aminoglycoside exposure,
although this tends to be less severe and of later onset,3 4
and that nuclear-encoded modifier genes may increase
penetrance of the mutation in such cases.5 The
m.1555A>G mutation has also been reported to cause
age-related hearing loss: in the Blue Mountains Hearing
Study, consisting of non-institutionalised permanent
residents of two suburban areas west of Sydney over the
age of 49, Vandebona et al 6 reported that mean auditory
thresholds were significantly higher in three of six
carriers of m.1555A>G compared with the general
population.
Aminoglycosides exert their antibacterial effects by
binding to the decoding region, specifically the amino-
acyl-tRNA acceptor site (or A site) of bacterial ribosomes,
altering their conformation.7 This destabilises
codoneanticodon pairing, resulting in codon
misreading that induces errors in protein synthesis.8 In
the human mitochondrion, mtDNA encodes 13 protein
components of the oxidative phosphorylation
(OXPHOS) system translated on mitochondrial ribo-
somes. Inaccurate mitochondrial translation may lead to
errors in these proteins, resulting in inefficient
OXPHOS, impaired ATP generation and increased
production of reactive oxygen species (ROS). Human
mitochondrial ribosomes bear a structural resemblance
to bacterial ribosomes, from which they evolved, but the
sequence at the decoding region in humans is different
from that at the corresponding site in bacterial ribo-
somes and does not normally allow aminoglycoside
binding. Mutation from adenine to guanine at position
1555 of the human mitochondrial 12S rRNA causes
a structural rearrangement which facilitates amino-
glycoside binding. The mechanism by which this muta-
tion causes deafness is unproven but is thought to
involve the generation of toxic ROS in the cochlear hair
cells.9
There is an argument for genetic testing prior to
aminoglycoside use, so that alternative antibiotics can be
selected for those with the mutation in order to prevent
lifelong deafness.1 However, costebenefit analyses also
take into account the observations that m.1555A>G may
cause later onset hearing loss in the absence of amino-
glycosides and that gradual hearing loss may be an
inevitable consequence of the mutation.10
We wanted to ascertain hearing levels in adults with
m.1555A>G in order to determine whether normal
hearing is preserved into middle age, an observation that
would strengthen the argument for genetic testing prior
to aminoglycoside usage.
METHODS
Design
We performed a population-based cohort study by
genotyping 7747 DNA samples from the 1958 British
birth cohort for the m.1555A>G mutation and
comparing the genotype with hearing outcome at
44e45 years. We haplogrouped those who had
m.1555A>G by GeneChip resequence analysis (see
below) to ensure that not all subjects belonged
to a single haplogroup that might be influencing
penetrance of the mutation.
Study population
The British 1958 cohort (also known as the National
Child Development Study) includes all births in
England, Wales and Scotland during 1 week in 1958.
From an original sample of over 17 000 births, survivors
were followed up at ages 7, 11, 16, 23, 33 and 42 and
at 44e45 by biomedical interview and test. Immigrants
of the same dates of birth were identified at ages 7, 11
and 16 and followed into adulthood, but adult immi-
grants (after age 16) have not been included. Data
collected up to age 42 by interviews with parents and
cohort members and at school medical examinations
include information on growth, health and health-
related behaviour, family background, socioeconomic
circumstances, behavioural, emotional and cognitive
development, educational achievement, employment,
psychosocial work characteristics, partnership and
pregnancy histories.
All eligible cohort members (ie, all except ‘permanent
refusals’) were invited to participate in a clinical exami-
nation by a trained research nurse visiting their home.
Following a period of piloting, this fieldwork started in
September 2002 and was completed in March 2004. The
visits were carried out by a team of over 120 specially
trained nurses from the National Centre for Social
Research, who conducted the annual Health Surveys of
England and Scotland. From a target sample of 12 069
persons, 9377 cohort members were visited. Eight
thousand eight hundred and ninety-four of these have
a valid hearing measure at 1 and 4 kHz.
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Blood samples were collected from 88% of those
examined, and 97% of these gave consent to creation of
immortalised cell lines and extraction and storage of
DNA for medical research purposes. Eight thousand and
eighteen blood samples were received from subjects who
gave consent to extraction of DNA, and 7980 of these
also gave consent for creation of immortalised
cell cultures. More details of the DNA collection are
available from the Access Committee for CLS Cohorts
website (http://www2.le.ac.uk/projects/birthcohort).
This study was approved by the SouthEast Multi-Centre
Research Ethics Committee.
Genotyping
Genotyping was performed by KBioscience (http://www.
kbioscience.co.uk; protocols available on request)
following successful ‘blind’ validation of the assay using
known positive and negative controls. Single-nucleotide
polymorphism (SNP) genotyping for m.1555A>G was
performed by competitive allele PCR (KASPar) (http://
www.kbioscience.co.uk/genotyping/genotyping-chemistry.
htm).1 Blanks and duplicate samples were included in all
plates for quality assurance purposes.
Seven thousand seven hundred and forty-seven
samples were genotyped. The 19 individuals who had
m.1555A>G were confirmed ‘in house’ by conventional
Sanger dideoxy termination cycle sequencing to have
the mutation, and haplogroups were constructed
from genotypes generated by GeneChip resequence
analysis.
GeneChip resequence analysis
The GeneChip Human Mitochondrial Resequencing
Array 2.0 (Affymetrix) was used to interrogate the entire
mtDNA sequence of the 19 individuals found to carry
the m.1555A>G mutation. The 16.5 kb mitochondrial
genome was amplified in two fragments using the
Expand Template Long PCR Kit from Roche Diagnostics
(Mannheim, Germany) according to the manufacturer’s
protocol.
PCR primers were Mito1-2F ACATAGCACATTACAGT
CAAATCCCTTCTCGTCCC, Mito1-2R ATTGCTAGGGT
GGCGCTTCCAATTAGGTGC-9307, Mito3F TCATTTT-
TATTGCCACAACTAACCTCCTCGGACTC and Mito3R CG
TGATGTCTTATTTAAGGGGAACGTGTGGGCTAT-7814.
Cycling conditions consisted of an initial denaturation
step of 3 min at 948C, followed by 10 cycles of denatur-
ation for 10 s at 948C, annealing for 30 s at 608C and
extension for 10 min at 688C; then 25 cycles of dena-
turation for 10 s at 948C, annealing for 30 s at 608C and
extension for 10 min + an additional 20 s per cycle at
688C and a final extension step of 10 min at 688C.
Concentration of DNA in the long PCR products was
determined using nanodrop spectrophotometry, and
equimolar concentrations of the two PCR products were
pooled. These were digested with DNAseI. Prehybrid-
isation, hybridisation, washing and scanning of the
GeneChip were performed according to the Affymetrix
CustomSeq Resequencing protocol. Sequences were
analysed using GSEQ 4.2 software. SNPs were automati-
cally called by GSEQ and presented in an SNP viewer
format. Haplogroups were assigned manually by exami-
nation of key defining polymorphisms (see table 2).
Pure tone audiometry at age 44e45 years
Pure tone audiometry was performed by air conduction
in each ear, at frequencies of 1 and 4 kHz according to
the British Society of Audiology recommended proce-
dure. MA25 portable audiometers with TDH 49
earphones in audiocups were used, calibrated to British
Standard BS EN ISO 389-1 (2000) (identical to ISO
389-1). Testing was carried out by the study research
nurses, who received training from experienced audiol-
ogists.11 Only information from completed tests was
used.
Statistical analysis
Hearing threshold in the better ear at two frequencies
(1 and 4 kHz), transformed by log transformation (log
(y+16.6) for 1 KHz and log (y+20.6) for 4 KHz) subject to
difference between ears being <20 dB (at 1 and 4 kHz),
was modelled by multiple regression in relation to family
history of hearing loss (yes/no), diabetes (age of onset
>20 years), gender, noise at work (>5, 1e5, <1 years,
none) with further control for noise at test (yes/no).
Those with conductive hearing loss in childhood (by
proxy measures at ages 7, 11) or with profound hearing
loss at ages 7 or 11 (>60 dB) were excluded. Modelling
was on the non-mutation (non-carrier) data. Ninety per
cent prediction intervals from this model were applied
to the mutation (carrier) data and are shown trans-
formed back to the dB scale in table 3. The model was
checked at both frequencies to rule out multicollinearity,
and plots of residuals against fitted values and normal
plots did not reveal any heteroscedasticity or non-
normality of residuals. No cases with high influence
(Cook’s distance) were found. Predictions from the
model and 90% prediction intervals are transformed
back to the raw scale.
As missing values on explanatory variables resulted in
only 18% of cases (1635 of 9532) with valid dependent
values being lost to analysis, it was not considered
necessary to use imputation or weighting methods to
compensate for this.
RESULTS
Genotyping
Genotyping using the KASPar competitive allele PCR
was successful for 7350 of 7747 individuals (table 1). Of
these, 19 had m.1555A>G, giving a prevalence of
0.26% (95% CI 0.14% to 0.38%) or 1 in 385 (95% CI 1 in
714 to 1 in 263). Both Sanger cycle sequence and
GeneChip resequence analyses confirmed that all 19
samples had m.1555A>G, as reported by GSEQ in
SNP viewer and by manual inspection of the mock
electropherograms.
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Haplogrouping of those with m.1555A>G was
performed by GeneChip resequence analysis to ensure
that subjects did not all belong to a single haplogroup
that might be influencing penetrance of the mutation.
All the haplogroups found were of European ancestry, as
expected in the British 1958 cohort (table 2, supple-
mentary table 1). The most prevalent haplogroup was ‘J’
followed by ‘U’ and finally ‘H’. This haplogroup preva-
lence was very similar to that of the Blue Mountains
cohort, in which two of five mutation carriers belonged
to haplogroup ‘J’, two to ‘U’ and one to ‘H’.6
Hearing comparison with non-mutation carriers
We compared hearing thresholds in the better hearing
ear at 1 and 4 kHz in those with and without the muta-
tion. Table 3 shows hearing data of 19 individuals
carrying m.1555A>G from the 1958 birth cohort with
90% prediction intervals. We found no significant
difference between the two groups at age 44e45 years.
One individual, subject 6, had a hearing threshold at
4 kHz that was above the 90% prediction intervals of the
model and one person, subject 9, had a threshold at
1 kHz that was below.
DISCUSSION
We have shown that 1 in 385 (95% CI 1 in 714 to 1 in
263) people in the British 1958 cohort have the
m.1555A>G mutation but that at age 44e45 years their
hearing is not significantly different from those without
the mutation. Data on aminoglycoside exposure have not
been prospectively collected in this cohort, but it is likely
that no one has been exposed to this major environ-
mental trigger and that the avoidance of aminoglycosides
in susceptible people can be expected to result in normal
hearing, at least until 44e45 years of age.
The normal hearing of the individuals identified in
this study suggests that m.1555A>G is a susceptibility
factor, requiring other environmental and/or genetic
factors to result in deafness, the most common envi-
ronmental interaction being aminoglycoside exposure.
The frequency of m.1555A>G of 1 in 385, together with
the normal hearing of mutation carriers in the 1958
birth cohort and previously in children of the ALSPAC
cohort who have the mutation,1 raises the question of
whether it is truly pathogenic. Both genetic and
biochemical evidence support its pathogenic role.
The frequency of this mutation in individuals who
have become deaf following aminoglycosides is 13%e
60%,12 13 a frequency far greater than that in the hearing
population; and in countries such as Spain and China,
where aminoglycosides are widely used, this mutation
accounts for 27% of cases of familial progressive deaf-
ness.4 In addition, biological data have demonstrated
defects in mitochondrial protein synthesis leading
to reduced OXPHOS in cell lines from affected indi-
viduals.14e16 These defects are caused by the mtDNA
mutation itself because they were transferred with
mutant mtDNA when enucleated patient cells were
fused with cells lacking mtDNA (r-zero cells) to make
transmitochondrial cybrids.16
It appears that the accuracy of correct amino acid
incorporation into synthetic polypeptides is reduced in
the presence of m.1555A>G, and more so in the pres-
ence of aminoglycosides, thereby causing reduced bio-
logical activity of the proteins assayed.8 Construction of
artificial bacterial hybrid ribosomes has demonstrated
that this effect was evident at 25-fold lower concentra-
tions of aminoglycoside compared with that observed
in non-mutant ribosomes, mimicking the enhanced
sensitivity of the mutation-bearing human ear to
aminoglycosides.
An unanswered question is why m.1555A>G appears
to cause only deafness, in the absence of nephrotoxicity
or other systemic effects typically seen in dose-related
aminoglycoside toxicity. We hypothesise that the stria
vascularis, a highly specialised metabolically active
layered epithelium rich in mitochondria which lines the
lateral wall of the cochlear duct, is the primary site of
aminoglycoside toxicity in individuals with the
m.1555A>G mutation. The stria is responsible for
energy-dependent transport of ions into the endolym-
phatic fluid of the cochlear duct compartment. This
generates a large positive extracellular potential, the
endocochlear potential (EP) of +80 to 100 mV and high
potassium concentration (150 mM) in the endolymph of
the cochlea, necessary for auditory transduction
(figure 1A). It is known that if energy-dependent ion
transport is inhibited, EP falls rapidly (figure 1B) and so
does hearing sensitivity.
Table 1 Genotyping results for m.1555A>G
Frequency Valid per cent
Valid A 7331 99.7
Valid G 19 0.3
Total 7350 100.0
Table 2 Haplogroup prevalence in 1958 cohort
Number of samples Percentage
Characterising single-
nucleotide polymorphisms Haplogroup
8 42 14766T, 4216T, 13708G J
6 32 14766T, 12308A, 10550G U
5 26 14766C, 7028C H
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We hypothesise that when aminoglycosides bind to the
decoding site of mutant mitochondrial ribosomes in the
stria, the marked reduction in fidelity of translation of
the OXPHOS proteins causes an energetic defect
resulting in a significant reduction in EP; this then
further attracts positively charged aminoglycosides into
the cochlear duct where they achieve a higher concen-
tration than usual. Because the EP is unique to the
cochlea and not generated in the vestibular system, the
toxic effects of m.1555A>G at ‘normal’ doses of
A B
C
Figure 1 Proposed mechanism for enhanced sensitivity of the cochlea to aminoglycosides. Aminoglycosides normally pass into
the endolymph in low concentrations because the endolymph is positively charged as are aminoglycosides. They then pass into
hair cells through auditory transduction channels on their apical surfaces. (A) In the presence of m.1555A>G, there is a reduction
in OXPHOS in the stria vascularis, a tissue packed full of mitochondria. Decreased ATP production is hypothesised to reduce the
endocochlear potential (EP) generated by the stria vascularis and to fall from its normal value of about +80 mV. The reduction in
positive potential attracts more positively charged aminoglycosides into the endolymphatic compartment and then into hair cells.
(B) The raised concentration of aminoglycosides in the endolymph, secondary to the fall in EP caused by inaccurate translation of
OXPHOS proteins, is unique to the inner ear and may explain why it alone is so sensitive to the effects of aminoglycosides in the
presence of m.1555A>G. (C) In the hair cells, the concomitant mitochondrial OXPHOS defect is associated with increased
production of reactive oxygen species (ROS) and generation of iron species (gentamicin acts as an iron chelator), causing
formation of a toxic aminoglycosideeiron complex (FeeAG). This activates molecular oxygen, which is reduced to superoxide by
an electron donor such as arachidonic acid, and results in formation of other ROS in a chain reaction. These activate apoptotic cell
pathways and cause hair cell death. AG, aminoglycosides; IeV represents complexes IeV of the mitochondrial OXPHOS system.
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aminoglycosides are observed only in the cochlea.17
From the endolymph, aminoglycosides then pass into
the cochlear sensory hair cells through mechano-
transduction channels in their apical surface, which
open in response to sound. Once in the hair cells, the
half-life of aminoglycosides is extremely long; animal
studies have shown that aminoglycosides are detectable
in cochlear hair cells for up to 6 months after adminis-
tration, so increased concentration of aminoglycosides in
the endolymph is likely to result in rapid accumulation,
at what are considered to be ‘normal’ drug levels.18 19
Finally, the concomitant pre-existing mitochondrial
OXPHOS defect within the hair cells themselves is
associated with increased production of ROS and
generation of iron species. The iron species bind to
aminoglycosides to produce a toxic complex, which
mediates cochlear cell death via apoptosis (figure 1C).
In addition to aminoglycoside-induced ototoxicity,
m.1555A>G has also been reported to cause non-
syndromic hearing loss without aminoglycoside expo-
sure. However, in those families, hearing loss was less
severe and of later onset.3 4 It has been proposed that in
such families there is an additional genetic modifier
which causes hearing loss in the absence of amino-
glycosides. One such modifier, the A10S variant in the
gene encoding TRMU, a mitochondrial protein related
to transfer RNA (tRNA) modification, was also assayed in
our cohort but no one with m.1555A>G was homozy-
gous for this variant and so we cannot assess whether
hearing threshold might be influenced by this additional
variant. Clearly, in the UK, both in the 1958 cohort and
the ALSPAC cohort, there does not appear to be any
evidence that m.1555A>G causes non-syndromic
hearing loss in our population. Recently, Vandebona
et al 6 reported that m.1555A>G causes age-related
hearing loss: mean auditory thresholds were significantly
higher in three of six carriers of m.1555A>G compared
with the general population. We find no such effect.
However, their population was significantly older than
the 1958 cohort, and we cannot exclude that those with
m.1555A>G in our cohort will experience deterioration
in hearing thresholds greater than would be expected
for their age in later life.
Our work describes the findings in a birth cohort on
whom hearing data have been collected prospectively
and as a result avoids some of the biases which are
inherent in studies related to deafness and hearing loss.
It confirms our previous prevalence figures, and since
the cohort is not a geographical one, it does not suffer
from the potential confounder that all individuals with
the mutation could share a common (local) ancestor. In
fact, we have excluded this possibility by demonstrating
that the mutation has arisen on a number of different
European mitochondrial haplogroups. Nevertheless,
a potential limitation of the study was that data on
aminoglycoside exposure were not collected and that in
three of the 19 subjects hearing thresholds could not be
predicted because information required for modelling
was missing. However, their measured hearing thresh-
olds appear to be well within accepted criteria
for normality. Further sources of bias could be secondary
to genotyping failures, particularly if mutation carriers
with raised hearing thresholds were over-represented in
this group. In addition, it is possible that samples
with low heteroplasmy levels may not have been detected
by the KASPar genotyping method, possibly leading to
an underestimate of the mutation frequency in this
cohort.
Our finding of normal hearing in adults with
m.1555A>G up to the age of 44e45 has considerable
implications for public health globally as well as routine
clinical practice. Global usage of aminoglycosides is
likely to increase, particularly with the emergence of
multidrug-resistant tuberculosis (MDR-TB) since these
are cheap antimicrobial agents with broad spectrum
coverage recommended as second-line treatment for use
in MDR-TB. Over half a million new cases of MDR-TB are
reported per year, with a likely global prevalence of at
least two to three times that figure.20 We have confirmed
that m.1555A>G is common (almost 1 in 400 individ-
uals) and showed previously that it is associated with
normal hearing in childhood.1 Therefore, many people
at risk of aminoglycoside-induced hearing loss are likely
to have normal hearing if they have not been exposed to
aminoglycosides and will not be suspected of being
susceptible by any means other than genetic testing.
Rapid genetic testing prior to aminoglycoside adminis-
tration would be ideal in order to prevent avoidable
deafness21 22 because those who have the mutation
should be prescribed alternative antibiotics. Currently,
all genetic screening is performed on an elective basis
rather than in an acute situation because no rapid
testing is available. Premature neonates pose a particular
problem since they cannot be electively tested and
aminoglycosides are widely used for the treatment of
suspected neonatal sepsis, where they are highly effective
and drug resistance is low. Developing countries are also
a major concern since aminoglycoside usage is likely to
increase together with MDR-TB.
In conclusion, the m.1555A>G mutation predisposing
to aminoglycoside ototoxicity is prevalent in Caucasian
populations, with a frequency of 1 in 385 in the 1958
British birth cohort. Reassuringly, normal hearing is
maintained until 44e45 years in individuals with the
mutation. This is one factor that would favour screening
for this mutation prior to aminoglycoside administration
to avoid preventable deafness. However, arguments
around preemptive pharmacogenetic testing are often
complex and based on models with missing information;
we concur that further research is needed to inform the
case.23
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